Trastuzumab Recruiting Phase 3 Trials for HER-2 Positive Breast Cancer / Neoplasms, Metastatic Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02492711Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer